Sclerostin antibody (Scl-Ab) and parathyroid hormone (PTH) are bone-forming agents that have different modes of action on bone, although a study directly comparing their effects has not been conducted. The present study investigated the comparative quantitative effects of these two bone-forming agents over time on bone at the organ, tissue, and cellular level; specifically, at the level of the osteoblast (Ob) lineage in adolescent male and female rats. Briefly, eight-week old male and female Sprague-Dawley rats were administered either vehicle, Scl-Ab (3 or 50 mg/kg/week subcutaneously), or human PTH (1-34) (75 μg/kg/day subcutaneously) for 4 or 26 weeks. The 50 mg/kg Scl-Ab and the PTH dose were those used in the respective rat lifetime pharmacology studies. Using robust stereological methods, we compared the effects of these agents specifically at the level of the Ob lineage in vertebrae from female rats. Using RUNX2 or nestin immunostaining, location, and morphology, the total number of osteoprogenitor subpopulations, Ob, and lining cells were estimated using the fractionator or proportionator estimators. Density estimates were also calculated referent to total bone surface, total Ob surface, or total marrow volume. Scl-Ab generally effected greater increases in cancellous and cortical bone mass than PTH, correlating with higher bone formation rates (BFR) at 4 weeks in the spine and mid-femur without corresponding increases in bone resorption indices. The increases in vertebral BFR/BS at 4 weeks attenuated with continued treatment to a greater extent with Scl-Ab than with PTH. At 4 weeks, both Scl-Ab and PTH effected equivalent increases in total Ob number (Ob.N). Ob density on the formative surfaces (Ob.N/Ob.S) remained similar across groups while mineral apposition rate (MAR) was significantly higher with Scl-Ab at week 4, reflecting an increase in individual Ob vigor relative to vehicle and PTH. After 26 weeks, Scl-Ab maintained BFR/BS with fewer Ob and lower Ob.N/Ob.S by increasing the Ob footprint (bone surface area occupied by an Ob) and increasing MAR, compared with PTH. The lower Ob.N and Ob.N/Ob.S with Scl-Ab at 26 weeks were associated with decreased osteoprogenitor numbers compared with both vehicle and PTH, an effect not evident at week 4. Osteoprogenitor numbers were generally positively correlated with Ob.N across groups and timepoints, suggesting dynamic coordination between the progenitor and Ob populations. The time-dependent reductions in subpopulations of the Ob lineage with Scl-Ab may be integral to the greater attenuation or self-regulation of bone formation observed at the vertebra, as PTH required more Ob at the formative site with correlative increased numbers of progenitors compared with Scl-Ab indicating potentially greater stimulus for progenitor pool proliferation or differentiation.
Introduction
Sclerostin antibody (Scl-Ab) and parathyroid hormone (PTH) are bone-forming agents that have different modes of action on bone. In animals, Scl-Ab increases cancellous and cortical bone mass predominately through increased modeling-based bone formation, with effects on bone resorption that are either neutral or inhibitory [1] . This increase in bone formation is effected initially by activation of bone lining cells (L.Ce) [2] , with bone formation maintained presumably through recruitment of progenitors to the formative surface. In contrast, data in both animals and humans have demonstrated that intermittent PTH increases cancellous bone mass largely by increasing the remodeling rate with increased bone formation coupled to increased bone resorption and a net positive bone balance at the basic multicellular unit level [3, 4] . Modeling-based formation has also been shown to contribute to the initial response to PTH by activation of L.Ce [5, 6] , similar to Scl-Ab, but the extent of modeling-based formation is substantially less than that with Scl-Ab [7, 8] . Although both agents have been demonstrated to increase cortical bone mass, data in humans suggest that these effects are greater with Scl-Ab [9] at clinical doses. In addition, intracortical remodeling is not systemically increased with Scl-Ab in primates [10] , unlike the effects of PTH [11, 12] .
With chronic administration, both agents display attenuation of the stimulation of bone formation biomarkers but with apparent differences in temporal patterns, most recently illustrated in a comparative clinical trial with the Scl-Ab, Romosozumab [9] . Romosozumab effected transient increases in bone formation markers maximal at 1 month, returning to or below baseline by 2-9 months, accompanied by a sustained moderate decrease in resorption marker. In contrast, PTH affected a sustained increase in both formation and resorption markers over the 12-month treatment period, with maximal increase in formation markers at 6 months. Although the human skeleton is composed primarily of cortical bone, cancellous bone contributes a larger surface area. With similar remodeling rates, cancellous bone would therefore have a greater contribution to circulating bone biomarkers [13] . Thus the temporal pattern of changes in bone biomarkers in the comparative clinical trial suggests that the attenuation of cancellous bone formation occurs more rapidly with Scl-Ab compared with PTH. The increase in bone formation occurred in the face of sustained suppression of bone resorption with Scl-Ab, in contrast to sustained increased resorption with PTH. Animal studies with Scl-Ab indicate that although bone formation rate attenuates on cancellous surfaces following 6 months of dosing, endocortical formation is maintained and resorption parameters remain lower on bone surfaces [14] . Although animal studies assessing the temporal changes associated with chronic PTH treatment are limited in number and scope, the increases in bone formation in humans also progressively decrease in cancellous bone following 18 months of dosing, with the bone-forming effects of PTH on the endocortex appearing to be temporally coupled with the attenuation in cancellous bone [15] .
Although the comparative clinical trial illustrated differential effects between the Scl-Ab, romosozumab, and PTH on bone formation markers and bone mineral density (BMD), a study directly comparing their effects at the tissue level in cancellous and cortical bone has not been reported. To this end, we conducted a study comparing the temporal changes in bone biomarkers, mass, and histomorphometric indices of bone formation and resorption in cancellous and cortical bone in male and female rats administered Scl-Ab and PTH. Because these agents exploit different modes of bone formation to increase bone mass, we hypothesized that these differences are related to or reflected in differential effects on the osteoblast (Ob) and osteoprogenitor subpopulations. Therefore, unbiased stereological methods were employed to obtain estimates of number of Ob, L.Ce, and subpopulations of osteoprogenitors to explore the potential differential quantitative effects of these agents on the Ob lineage over time.
Methods

Study design
Male and female Sprague-Dawley (CD®IGS) rats (Charles River Laboratories, Hollister, CA), 148/sex and 8 weeks of age, were divided into four treatment groups: vehicle (Veh) (n = 20/sex), 3 mg/kg Scl-Ab (n = 70/sex), 50 mg/kg Scl-Ab (n = 38/sex), and 75 μg/kg human PTH (1-34) (n = 20). Because the Scl-Ab used in this study, romosozumab, is immunogenic in rats, Scl-Ab groups were powered to allow for removal of rats that developed anti-drug antibodies (ADA) from the study since ADAs can attenuate exposure and pharmacological response. Rats were assigned to treatment groups using a computerized blocking procedure (Pristima Version 6.1.0 Build 45, Xybion Corp., Morris Plains, NJ) designed to achieve body weight balance with respect to treatment groups. Scl-Ab (romosozumab, 34.97 mg/mL) and Veh (55 mM acetate, 13 mM calcium, 6% sucrose, 0.006% polysorbate 20, pH 5.2) were administered by subcutaneous (SC) injection weekly at a dose volume of 1.43 mL/kg. hPTH (1-34) (human parathyroid hormone H-483; Bachem, Torrence, CA) was administered daily by SC injection. PTH was reconstituted with sterile water, aliquoted in vials and stored at − 60°C until day of use, then diluted to 0.15 mg/mL in buffer (2% bovine serum albumin, 0.001 N HCl, 0.15 M NaCl) for injection at a dose volume of 0.5 ml/kg. All dosing was performed in the morning (prior to approximately noon) within the home animal room or at the home cage; Veh animals were dosed first, followed by the Scl-Ab and PTH-treated animals.
One cohort of rats was dosed for 4 weeks and the second cohort was dosed for 26 weeks. Serum was collected from Scl-Ab-treated rats on study day (D) 29 (week-4 necropsy), D85, and D183 (week-26 necropsy) and analyzed for ADA and serum drug concentrations. ADA assay and serum drug concentration results were used to confirm adequate drug exposure throughout the study. All ADA-positive animals were excluded from the study, with further reductions in ADA-negative animals when required to reduce the group size for subsequent analyses to 10/sex/timepoint, based on assigned animal number. Data from these animals were used for statistical analysis and study interpretation.
Serum was collected from the week 26 cohort on D7, D57, D120, and D183 (±2 days) for bone biomarker analyses that included N-terminal type I procollagen (P1NP), osteocalcin (OC), tartrate-resistant acid phosphatase-5b (TRACP-5b), and collagen type 1 cross-linked Ctelopeptide (CTx). Rats were administered the fluorochrome calcein green (10 mg/kg SC; Sigma-Aldrich, St. Louis, MO) 10 and 3 days prior to necropsy for dynamic histomorphometry. Fluorochrome solution was prepared on each morning of administration in 2% sodium bicarbonate in saline at a concentration of 10 mg/mL and filter sterilized (0.22 μm syringe filters).
For euthanasia, animals were anesthetized with isoflurane/oxygen and then exsanguinated. At necropsy, vertebrae T13-L2, left and right tibia, and left humerus were collected for routine histopathological evaluation of bone marrow and Ob morphology. Vertebra L3 and left femur were collected and fixed in 70% ethanol for peripheral quantitative computed tomography (pQCT) analysis. Vertebra L4, right femur diaphysis, and right femur distal metaphysis were collected, fixed in 10% neutral buffered formalin (NBF) for 48 h, transferred to 70% ethanol and then processed in methyl methacrylate undecalcified for histomorphometric analyses. L6 vertebral body was collected, fixed in 4% paraformaldehyde (PFA) at 4°C for 48 h, decalcified in 10% EDTA with 2% PFA at 4°C until decalcified, and then processed in paraffin for stereological analyses.
All animals were cared for in accordance to the Guide for the Care and Use of Laboratory Animals, 8th Edition [16] . Animals were group-housed (two per cage) at an Association for Assessment and Accreditation of Laboratory Animal Care, international-accredited facility in nonsterile, ventilated, microisolator housing with corn cob bedding. All research protocols were approved by the Institutional Animal Care and Use Committee. Animals had ad libitum access to pelleted feed (Rodent Diet 2020X, Teklad Diets, Madison, WI) and water (reverse osmosis purified) via an automatic watering system. Animals were maintained on a 12:12 h light:dark cycle in rooms with controlled temperature (72°F +/− 2) and humidity (30-70%) and had access to enrichment opportunities (Nylabones and Rat Retreats or Rat Tunnels).
Serum biomarkers
Whole blood (700 μL) collected from the tail vein was transferred to a serum separator tube (Microtainer; Becton Dickinson, Franklin Lakes, NJ). Serum OC was measured using a rat OC single-plex Milliplex kit (RBN-31K-1OC; Millipore, Billerica, MA), and CTx was measured using RatLaps (IDS, Gaithersburg, MD). Systemic TRACP-5b and P1NP were evaluated by enzyme immunoassays (Rat TRACP and Rat/Mouse PINP, IDS, Gaithersburg, MD). All assays were performed in accordance with manufacturer protocols.
pQCT
The left femur was scanned with a Stratec XCT Research M instrument (Norland Medical Systems, Fort Atkinson, WI). The length of the femur was measured with precision calipers and cross-sectional scans were performed at two sites: 50% of the length from the distal end for cortical analyses and 25% of the length from the distal end for metaphyseal (trabecular) analyses. Measurements were performed with a voxel size of 0.1 mm using software version 5.40. Cortical bone was defined and analyzed using contour mode 2 and cortical mode 4, with an outer threshold of 340 mg/cm 3 . Trabecular bone of the distal metaphysis was defined using peel mode 1 without further thresholding; volumetric bone mineral content (vBMC) and volumetric BMD (vBMD) were determined in the inner 30% of the total area.
The length of the vertebral body was measured with precision calipers from the cranial to the caudal ends, and a cross-sectional scan was performed at 50% of the length of the body. The Stratec instrument was used for the vertebral scans as described above for the femur, including use of the same voxel size, outer threshold, and peel mode for collection of data listed for the distal femoral metaphysis.
Qualitative histopathology
Bones collected for routine histopathology were fixed for 48 h in NBF, transferred to 70% ethanol, routinely processed in paraffin, sectioned at 4 μm, and stained with hematoxylin and eosin. Sections were evaluated by light microscopy for alterations in bone marrow or Ob morphology.
Bone histomorphometry
Undecalcified stained and unstained sections of vertebrae L4 and femur metaphysis and ground cross sections of mid-shaft femur were prepared and evaluated/expressed as described previously [17, 18] .
Stereological analysis of Ob lineage
Vertebrae L6 from females in all groups at weeks 4 and 26 were used for estimation of total number of subpopulations of the Ob lineage. The stereological estimator, the physical fractionator [19] , was used to provide estimates of total number of runt-related transcription factor 2 (RUNX2)-immunopositive subpopulations including Ob, L.Ce, peritrabecular osteoprogenitors (PTb.Op), and marrow osteoprogenitors (Ma.Op) in cancellous bone. Number estimates by these methods are independent of size, shape, distribution, or orientation. The physical fractionator uses physical disectors (ie, paired consecutive thin sections that constitute a three-dimensional [3-D] probe [volume] in which cells are counted; number is zero-dimensional and therefore must be estimated in a 3-D probe). The disector counting principle uses a unique counting feature of the cell, in this case the nucleus, and a cell is only counted when the nucleus is present in a sampled field in one section of the disector (counting field) and not the other (lookup field) [20] . To estimate number of nestin-immunopositive marrow stromal cells (Ma.St.Ce), the proportionator estimator was used [21] . A combination of immunophenotyping, morphology, and location was used to classify cells for estimation ( Fig. 1 ). Further details of immunohistochemical and stereological methods are provided in Supplemental materials.
Statistical analyses
All data were analyzed using SAS V9.1.2 in the Windows Vista Professional environment. All statistical analyses were conducted by gender and all group and time effects were considered statistically significant at p b 0.05. Dual-energy X-ray absorptiometry, pQCT, histomorphometry, and stereology endpoints were analyzed using a two-way analysis of variance (ANOVA) model with cohort (4-week cohort vs 26-week cohort), treatment group (Veh, 3 mg/kg Scl-Ab, 50 mg/kg Scl-Ab, and, 75 μg/kg hPTH 1-34), and the two-way interaction between cohort and treatment group as fixed effects. The variance structure of the model was determined by selecting among four variance structures: 1. equal variances across treatment groups and equal variances across cohorts, 2. unequal variances across treatment groups and equal variances across cohorts, 3. equal variances across treatment groups and unequal variances across cohorts, and 4. unequal variances across treatment groups and unequal variances across cohorts using the AICC criterion (Akaike information criterion with a correction for finite sample sizes). When there was a convergence issue, the two-way ANOVA was applied to the ranks of the original data. When ties were prevalent, Wilcoxon-exact test was also performed in addition to twoway ANOVA to help evaluate how sensitive the results were to ties and to achieve robust statistical interpretation of the results. Pairwise comparisons (3 mg/kg Scl-Ab vs Veh, 50 mg/kg Scl-Ab vs Veh, PTH vs Veh, and 50 mg/kg Scl-Ab vs PTH) were performed and a multivariate-t correction method was used to adjust for multiple comparisons.
Serum bone biomarker end points collected on week-26 cohorts were each analyzed using a one-way ANOVA model with treatment group as a fixed effect for each sample collection time. As described above, the AICC criterion was used to determine the variance structure across treatment groups for each ANOVA model. Pairwise comparisons and multivariate-t correction multiple comparison adjustments were performed as described above.
Results
Comparative effects of Scl-Ab and PTH on bone biomarkers
In females, an early robust increase in bone formation in response to Scl-Ab at 50 mg/kg was evident by increases in serum OC and P1NP at D7 relative to Veh controls ( Fig. 2 ) which attenuated over time but remained elevated relative to Veh at D182. The increase in bone formation markers associated with PTH was delayed in females until D57, with increases in OC generally sustained through D182 ( Fig. 2A-B ). CTx was transiently increased at D7 with 50 mg/kg Scl-Ab but was similar to Veh through the remainder of the timecourse. In contrast, CTx was increased significantly by D57 with PTH and remained elevated at D182 (Fig. 2C ).
In males, PTH resulted in the greatest increases in P1NP and OC, with sustained increases through D182 at a level 2-fold that of the Veh group and significantly greater than the 50 mg/kg Scl-Ab group ( Fig. 2D -E). A slight transient increase in CTx at D7 was observed in males treated with 3 mg/kg Scl-Ab, also observed in females treated with 50 mg/kg. Significant increases in CTx were observed in PTH males at D7 and D57 ( Fig. 2F) . Absolute values for serum biomarkers are provided in Supplemental Table 1 .
Comparative effects of Scl-Ab and PTH on bone mass
Ex vivo pQCT analyses of L3 and the distal femur metaphysis demonstrated increased bone mass in Scl-Ab and PTH groups after 26 weeks, as shown in females in Fig. 3 . These increases were reflected in dosedependent increases in total vBMC, with 50 mg/kg Scl-Ab affecting the greatest increases at both sites, to levels that were greater than those with PTH ( Fig. 3A) . The greater bone mass reflected increases in the trabecular compartment, with significant gains in vBMD by pQCT and bone volume (BV/TV) by histomorphometry ( Fig. 3B -C). In males, the increases in bone mass were similar to the females, although the greatest increases in distal femur bone mass parameters were with PTH treatment (Supplemental Table 2 ). Comparison with data collected after 4 weeks of treatment demonstrate the expected age-dependent increases in bone mass in Veh groups with more pronounced progressive increases in Scl-Ab and PTH groups (Supplemental Table 3 ). Notable was a more rapid increase in bone mass in the distal femur in PTH males at 4 weeks (Supplemental Table 2 ).
In females at week 26, femur diaphyseal cortical vBMC was significantly increased by 11% and 53% in the PTH and 50 mg/kg Scl-Ab groups, respectively (Fig. 3D ). The gains in cortical bone mass were associated with similar reductions in endocortical (Ec.) perimeter in both groups, while only 50 mg/kg Scl-Ab significantly increased periosteal (Ps.) perimeter ( Fig. 3E -F and Supplemental Table 3 ). Similar improvements in cortical bone parameters were found in males treated with Scl-Ab and PTH for 26 weeks, though the increases in vBMC were more similar in magnitude (Supplemental Table 2 ).
Comparative histopathology of Scl-Ab and PTH
Qualitative evaluation of tibia, humerus, and vertebrae from males and females at 4 and 26 weeks revealed a minimal increase in peritrabecular stromal cells in PTH-treated rats in the proximal metaphysis of tibia (seven of 10 males) and humerus (three of 10 males; three of 10 females) at 4 weeks, which was not present at 26 weeks (Supplemental Fig. 1 ). These cells likely represent osteoprogenitors as previously characterized [22] . The increase in peritrabecular stromal cells at 4 weeks may correlate with the more rapid increase in metaphyseal trabecular bone in PTH-treated males. Rare foci of woven bone were observed at a low incidence in the long bone in PTH-treated females at 4 and 26 weeks, typically in the epiphyseal cancellous bone or in the distal metaphysis (Supplemental Fig. 2 ). In both PTH and Scl-Ab-treated rats, Ob hyperplasia was not observed and Ob morphology varied as expected, dependent upon the age of the associated formative surface.
Comparative effects of Scl-Ab and PTH on bone histomorphometry
Consistent with the increases in serum biomarkers and trabecular and cortical bone mass, both Scl-Ab and PTH resulted in increases in histological bone formation parameters in L4, distal femur metaphysis, and femur diaphysis. As these effects were generally similar across sexes, the data from female rats are presented in Figs. 4 and 5 and Supplemental Table 4 , while male data are provided in Supplemental Table 5 .
In L4 and distal femur cancellous bone, marked significant increases in mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) were observed at week 4 with 50 mg/kg Scl-Ab. These parameters decreased in all treatment groups with age but remained significantly increased with 50 mg/kg Scl-Ab relative to Veh at week 26. For BFR/BS at L4, the Scl-Ab-mediated increases in BFR/BS attenuated from 12-fold to 3-fold and from 6.3-fold to 0.6-fold, from week 4 to 26 in female and male rats, respectively, relative to Veh (Table 1 ). This relative attenuation was not observed at the distal femur. PTH also significantly increased these parameters at week 4, to levels that were generally lower than values at 50 mg/kg Scl-Ab, except for the male distal femur where PTH had the greater effects (Supplemental Table 5 ). At week 26 in L4, PTH resulted in a 3.4 fold increase in BFR/BS from Veh in females, with BFR/BS in males essentially at Veh values (Table 1) . Consistent with the observed increases in cancellous BV/TV, bone formation was increased with 3 mg/kg Scl-Ab at these sites but to a lesser degree than that with 50 mg/kg Scl-Ab. At the distal femur, significant increases were observed for MS/BS and BFR/BS in both sexes and at both timepoints with 3 mg/kg Scl-Ab relative to Veh, while significant increases in these parameters in L4 were only observed at week 4 in males ( Fig. 4 and Supplemental  Table 5 ).
Effects on trabecular bone resorption were limited to modest significant increases in osteoclast surface (Oc.S/BS) with PTH at weeks 4 and 26 in L4 in both sexes relative to Veh, and a modest significant decrease with PTH at the distal femur in males at week 4 ( Fig. 4D and Supplemental Tables 4 and 5 ). Across all groups and sites, there was an agedependent decrease in Oc.S/BS from week 4 to 26. At the femur diaphysis, only 50 mg/kg Scl-Ab significantly increased periosteal labeled perimeter (Ps.L.Pm) and Ps.BFR/BS at week 4 with sustained increases in Ps.L.Pm evident at week 26 in females. Ps.BFR/ BS at week 26 was similar to Veh due to the significant age-related decrease in Ps.MAR, evident in all treatment groups ( Fig. 5A-C) . At the endocortical surface, Ec.MAR and Ec.BFR/BS in females treated with 50 mg/kg Scl-Ab was significantly lower than PTH at week 4, however at week 26, Ec.BFR/BS was increased compared with Veh-and PTHtreated females (Fig. 5D -F and Supplemental Table 3 ). Significant increases in endocortical labeled perimeter (Ec.L.Pm) and Ec.MAR accompanied the increased Ec.BFR/BS ( Fig. 5D-F) . A majority of cortical samples in the Veh groups at week 26 did not contain double labels on the endocortex, thus an imputed value of 0.3 μm was used for Ec.MAR. The cortical effects with 3 mg/kg Scl-Ab were limited to significant increases in Ec.L.Pm and Ec.MAR at week 26 in males (Supplemental Tables 4 and 5) .
Although neither Scl-Ab nor PTH affected longitudinal growth rate (LGR) at the distal femoral metaphysis at week 4 or 26, PTH significantly increased femoral bone length at 26 weeks. Time-dependent effects on bone length and LGR were observed in all groups as a consequence of aging (Supplemental Table 6 ). Fig. 3 ). MS/BS was slightly but consistently lower than Ob.S/BS at both timepoints across all groups, which may reflect differences between a 2-D and 3-D estimate, the regions of interest, or the timing of bone formation.
Ob.S was increased in the 50 mg/kg Scl-Ab and PTH groups at both weeks 4 and 26, consistent with 2-D surface-referent dynamic parameters (Fig. 6A ). Ob.S was significantly attenuated at week 26 compared with week 4 in Veh and Scl-Ab at 50 mg/kg. Corresponding increases in Ob.N were observed in the 50 mg/kg Scl-Ab and PTH groups at both timepoints but were significantly attenuated at week 26 with 50 mg/kg Scl-Ab compared with week 4 (Fig. 6B ). The lack of significant reduction in these parameters in the PTH group at week 26 is consistent with more constant sustained bone formation, more evident with the sensitive 3D estimates. In the Veh and 3 mg/kg Scl-Ab groups, Ob.S significantly decreased with age from week 4 to 26, with Ob.N sustained over the same period.
To assess the relative effects of Scl-Ab and PTH on the number of Ob contributing to bone formation on active formative sites, Ob density (Ob.N/Ob.S; the number of Ob per unit of Ob.S) and its inverse, Ob footprint (Ob.Fp; the amount of Ob.S interfaced with an individual Ob), were calculated ( Fig. 6C-D) . From week 4 to 26 in the Veh and 3 mg/kg Scl-Ab groups, Ob.N/Ob.S increased, resulting in a decrease in Ob.Fp. Although no effect of 50 mg/kg Scl-Ab or PTH on these parameters was observed at week 4, significantly lower Ob.N/Ob.S and greater Ob.Fp were observed at week 26 with both agents, compared to Veh. These week 26 indices were generally maintained at levels similar to those in all groups at week 4, although the decrease in Ob.N/BS with 50 mg/kg Scl-Ab exceeded that of PTH, resulting in relatively lower Ob.N/Ob.S and greater footprint on a formative surface.
Linear regression analysis revealed a time-dependent change in the relationship of Ob.N/BS and MS/BS, both referent to total bone surface (BS). As expected, a positive correlation of Ob.N/BS and MS/BS was observed at week 4 (overall r 2 = 0.63, p b 0.0001), with Veh and 3 mg/kg Scl-Ab clustered at lower Ob.N/BS and MS/BS values, PTH intermediate in values, and 50 mg/kg Scl-Ab at the upper end of the regression (Fig. 6F ). Although the correlation remained positive across groups at week 26, it was weaker (overall r 2 = 0.24, p = 0.001), with the slope of the regression line shifted lower and the distribution of the groups changed (Fig. 6G) . Ob.N/BS values for 50 mg/kg Scl-Ab were similar to those for Veh at week 26, despite MS/BS values that were higher and maintained in the range of PTH. Interestingly, although the data observed with Veh and 3 mg/kg Scl-Ab treatment remained clustered at the low end of the regression at week 26, MS/BS values decreased relative to week 4, while Ob.N/BS values remained in the week 4 range, suggesting a decline in Ob function with age.
The observation that 50 mg/kg Scl-Ab effectively maintained MS/BS values equivalent to PTH with lower Ob.N suggested that Scl-Ab increased activity at the level of the individual Ob (ie, enhanced Ob vigor to maintain bone formation with fewer Ob). Regression analysis of Ob.Fp, the amount of active forming bone surface "serviced" by an individual Ob, and MAR demonstrated a positive correlation at weeks 4 ( Fig. 6H ) and 26 ( Fig. 6I) . At week 4, although all groups spanned a relatively comparable range of Ob.Fp values, the highest MAR values were associated with 50 mg/kg Scl-Ab. At week 26, Ob.Fp values were markedly shifted towards the higher values with 50 mg/kg Scl-Ab, with similar or slightly higher MAR values as the other groups. Although MAR provides a traditional histological assessment of Ob vigor, a new vigor index (Ob.S*MAR/Ob.N) was calculated using the stereological data to reflect the total bone formed per Ob. Ob.S*MAR/Ob.N was significantly increased at both timepoints in the 50 mg/kg Scl-Ab relative to Veh and PTH, and was shown to decline with age across all groups (Fig. 6E ). Together, these data indicated that Scl-Ab had a greater effect on Ob vigor compared with PTH.
Effects on osteoprogenitor populations
Three separate populations of osteoprogenitors were quantified to assess the effects of treatment and time on the Ob lineage at multiple stages. Total peritrabecular osteoprogenitor number (PTb.Op.N) represented the most mature osteoprogenitor adjacent to Ob, while more immature osteoprogenitors located in the marrow were characterized as Ma.Op and Ma.St.Ce. At week 4, no significant treatment effects were observed on these three osteoprogenitor populations ( Fig. 7A-C) . At week 26, PTb.Op.N and number of Ma.Op (Ma.Op.N) were dosedependently reduced in the Scl-Ab groups relative to Veh, while PTH reduced Ma.Op.N but not PTb.Op.N. With 50 mg/kg Scl-Ab, the decreases in PTb.Op.N and Ma.Op.N from week 4 to 26 were significant, resulting in a mean value that was significantly lower than the PTH group. The temporal decreases with Scl-Ab contrasted to the increases in these osteoprogenitors observed with aging in Veh. The number of Ma.St.Ce (Ma.St.Ce.N) was not significantly changed by Scl-Ab or PTH at week 26 relative to Veh, although 50 mg/kg Scl-Ab resulted in a significantly lower mean value relative to PTH. Time-dependent decreases in Ma.St.Ce.N were observed in the Veh and Scl-Ab groups that achieved significance at 3 mg/kg Scl-Ab. Overall, these data suggest that Scl-Ab effected reductions in all three osteoprogenitor pools with chronic treatment relative to Veh and/or PTH.
Because the osteoprogenitor populations support the demands for Ob, the relationship of each osteoprogenitor population number to Ob.N was examined. Across all treatment groups, PTb.Op.N was significantly correlated with Ob.N at weeks 4 (r 2 = 0.63, p b 0.0001) and 26 (r 2 = 0.51, p b 0.0001; Fig. 7D) . Similarly, Ma.Op.N was positively correlated to Ob.N at weeks 4 (r 2 = 0.24, p = 0.0015) and 26 (r 2 = 0.15, p = 0.013; Fig. 7E ). Individual group regression lines were similar for these relationships at week 4; however, at week 26 the Veh data were shifted higher, reflecting greater numbers of osteoprogenitors relative to Ob. Presumably the earliest progenitor, Ma.St.Ce.N, only significantly correlated with Ob.N at week 26 (r 2 = 0.44, p b 0.001; Fig. 7F ) and showed a similar relationship across groups. The inverse of the regression line slope reflects the ratio of Ob to progenitor cells at each stage. At week 26, there were approximately two, three, and 25 Ob for every one PTb.Op, Ma.Op, and Ma.St.Ce, respectively. Additionally, at week 26, there was a positive correlation between the progenitor populations (Supplemental Fig. 4 ). Overall, the data suggest that progenitor cell population numbers are in a coordinated dynamic relationship with one another to meet the requirements for Ob demands on the bone surface.
BS and marrow volume (Ma.V) may have influenced the total number of osteoprogenitors, as both of these were affected by time and treatment (Supplemental Fig. 5 ). Therefore, PTb.Op.N were normalized to BS and the marrow progenitors (Ma.Op.N and Ma.St.Ce.N) were normalized to Ma.V for further evaluation (Fig. 7G-I) . These normalized cell densities were generally consistent with the total numbers, reflecting dose-dependent decreases in PTb.Op.N/BS and Ma.Op.N/Ma.V with Scl-Ab at week 26, while PTH did not change these parameters. At week 4, PTb.Op.N/BS and Ma.Op.N/Ma.V were significantly increased in the 50 mg/kg Scl-Ab and PTH groups. These normalized results suggest that the early response to Scl-Ab and PTH was to increase these progenitors to supply Ob to meet demands for the increase in Ob.S, an effect which was reversed with Scl-Ab treatment over time. Ma.St.Ce.N/Ma.V was reduced at week 26 in all groups except PTH, with the time-dependent reduction significant at 3 mg/kg.
Effects on L.Ce
The number of L.Ce (L.Ce.N) was decreased with 50 mg/kg Scl-Ab and PTH at week 4, consistent with the robust increases in bone formation on trabecular surfaces at this timepoint. From week 4 to 26, Scl-Ab at 3 and 50 mg/kg resulted in further decreases in L.Ce.N by 48% and 66%, respectively, while a significant decrease over time was not observed with PTH. At both timepoints, L.Ce.N was significantly less with 50 mg/kg Scl-Ab than with PTH ( Fig. 8A) . Normalization of L.Ce.N to quiescent bone surface (QS) reflected the L.Ce.N per surface (L.Ce.N/QS), while its inverse, lining cell footprint (L.Ce.Fp), reflects the surface occupied by each L.Ce. At week 4, L.Ce.Fp was decreased with 50 mg/kg Scl-Ab, perhaps reflecting a retraction of L.Ce due to the highly osteogenic state in this group and the extent of activation of modeling-based formation. However, at week 26, L.Ce.Fp was increased relative to Veh by 1.4-fold and 2-fold with 3 and 50 mg/kg Scl-Ab, respectively, with values with 50 mg/kg Scl-Ab significantly different from PTH, which was increased only modestly (Fig. 8B) .
Because changes in L.Ce number and density could be a consequence, at least in part, to changes in Ob.N/Ob.S, the linear correlation of Ob.Fp with L.Ce.Fp was explored. There was no significant correlation at week 4, but a significant positive correlation was observed at week 26 (r 2 = 0.33, p b 0.0001), with the strongest individual group correlations in the Scl-Ab-treated groups (3 mg/kg Scl-Ab, r 2 = 0.45; 50 mg/kg Scl-Ab, r 2 = 0.56) ( Fig. 8C-D) . These data suggest that potentially progressive reductions in Ob.N/Ob.S changes at the active bone formation sites contribute to reduced L.Ce density in response to Scl-Ab.
Discussion
The present study aimed to investigate the comparative quantitative effects of two bone forming agents, Scl-Ab and PTH, on bone at the organ, tissue, and cellular levels; specifically, at the level of the Ob lineage, in adolescent male and female rats. The findings illustrate that at high pharmacologic doses, the two agents display differences at 26 weeks of dosing. The highest doses used in this study were those used in the respective rat lifetime studies (Amgen, data on file) [23] . The discussion regarding comparison of these agents will focus primarily on these two dose groups.
The densitometric, histomorphometric, and bone biomarker findings in this study were not unanticipated, based on studies that have examined effects of these agents in studies in rats with Scl-Ab [14] and PTH analogs [24, 25] . Both agents increased cancellous mass in the distal femur and vertebrae but with some differences. Compared with PTH, Scl-Ab had comparatively greater effects on bone mass in the spine and distal femur as a consequence of higher cancellous BFR/BS at week 4 and, unlike PTH, occurred in the absence of increased Oc.S/BS at both timepoints. Both agents increased cortical bone mass, with effects of PTH limited to a relative increase in Ec.BFR/BS compared with Scl-Ab at week 4. Scl-Ab effected more rapid increases in cortical bone mass and elicited larger increases due to effects on both periosteal and endocortical surfaces. The pattern of effects on bone resorption and formation markers reflected tissue-based histomorphometric indices and the differences in the modes of bone formation between these two agents. The biomarker data illustrated the more pronounced attenuation of bone formation with Scl-Ab over time, which was reflected in a greater attenuation of L4 BFR/BS relative to Veh and PTH. Interestingly, although decreases in bone formation parameters were observed at the distal femur metaphysis and femur endocortex with aging, the increases with 50 mg/kg Scl-Ab relative to Veh did not attenuate. The results are consistent with previous reports in ovariectomized rats treated for up to 26 weeks [14] and may suggest that the temporal effects of Scl-Ab on bone formation are site-specific. In contrast, the bone forming effects of PTH did not attenuate significantly relative to Veh from week 4 to 26.
The more pronounced attenuation of bone formation, evident in the biomarkers and L4 histomorphometric data with chronic Scl-Ab treatment, was associated with quantitative differences in subpopulations of the Ob lineage compared with PTH that was revealed by stereological analyses. Although Ob.N increased at week 4 with both agents, Ob.N/ Ob.S remained similar to Veh. However, at week 26, both PTH and Scl-Ab had reduced Ob.N/Ob.S compared to Veh, maintaining values closer to that of younger rats. These effects were more pronounced with Scl-Ab, which had significantly lower total Ob.N, lower Ob.N/Ob.S, and greater Ob.Fp compared with PTH despite similar MS/BS. The differences in Ob.N/Ob.S between PTH and Scl-Ab may reflect different effects on the lifespan of the Ob and/or the number of progenitors recruited to the formative site. PTH has been demonstrated to inhibit Ob apoptosis in vivo [26] , an effect that could increase Ob.N/Ob.S. The effect of Scl-Ab on Ob lifespan in vivo is unknown. An increase in Ob apoptosis could contribute to the decreased Ob.N/Ob.S with chronic Scl-Ab administration, although this would not be consistent with reports that sclerostin promotes apoptosis in human Ob cells [27] and that decreased Ob apoptosis has been observed in transgenic mice expressing the Wnt-activating LPR5 mutation [28] . The increases in MAR with Scl-Ab could effect greater incorporation of Ob into bone matrix as osteocytes, which could contribute to the observed decrease in Ob.N/Ob.S. Differential effects on Ob.N/Ob.S may also be due to differences in recruitment of progenitors to the formative surface, with osteoprogenitor numbers reflecting those demands. There were positive correlations between total numbers of osteoprogenitor subpopulations with Ob.N as well as positive correlations among the progenitor populations. These results suggest that these progenitor cells are dynamically coordinated with one another to meet the demands and/or control the delivery of Ob to the bone surface. Although Ob and progenitor number were correlated, it is unclear which cell population is potentially driving changes in the other, or if the osteocyte is playing a role as a key regulator of the Ob and progenitor pools. When normalized for changes in bone surface area and marrow volume, RUNX2+ progenitors initially increased with both PTH and 50 mg/kg Scl-Ab. With chronic treatment, Scl-Ab resulted in a significant decrease in the progenitors despite maintaining bone formation that was similar to PTH. Both PTH and Scl-Ab have been reported to increase the number of osteoprogenitors in vivo in rodents [29] [30] [31] following a few weeks of treatment; however, the long-term effects of these agents on osteoprogenitor number in vivo have not been reported previously.
The mechanism for the significant down-regulation of progenitor number with Scl-Ab is unknown but likely contributed to the attenuation of bone forming effects in the lumbar spine. Nioi et al. [2] reported that Scl-Ab administration in rats resulted in gene expression changes that were consistent with cell cycle arrest in the mature Ob lineage by microarray after 1 week. If this expression pattern translates to the earlier progenitors with extended Scl-Ab dosing, this signature could explain the reduction in progenitor number. Gene expression changes related to the cell cycle have also been reported for PTH, although proand anti-proliferative effects appear to cycle daily with each injection [32] . The difference in the response of the progenitor pools to chronic treatment with Scl-Ab and PTH may be a reflection of these differences in gene expression; however, further longer-term transcriptional studies are needed. In addition, the use of other models, such as engineered mice, for lineage tracing would allow for more specific progenitor identification, quantification, isolation, and profiling to better understand the molecular mechanism mediating the changes in progenitor pools.
The analyses of the progenitor populations in this study were limited due to the availability of phenotypic markers for the Ob lineage in the rat and were restricted to populations that expressed RUNX2 or nestin. RUNX2 was used as a lineage marker based on its known role in osteoblastogenesis and its expression from osteoprogenitor to mature Ob to L.Ce. Nestin was used based on its description as a marker of the mesenchymal stem cells (MSC) [33] ; however, recent lineage tracing data in mice indicates that in developing bone, nestin marks a progenitor pool of both the Ob and endothelial cell lineage [34] . Therefore, it is an imperfect marker of the MSC. An additional limitation was that proliferation was not assessed in the progenitor populations, which would have allowed insight into the cell kinetics of these progenitors. Unfortunately, the lack of phenotypic markers for the progenitors that could be combined with nuclear proliferation markers precluded this assessment. In addition to differences in the Ob.N/Ob.S with chronic Scl-Ab or PTH treatment, differential functional effects at the individual Ob level were observed at both timepoints. At week 4, MAR was increased to a greater extent with Scl-Ab than with PTH or Veh, despite similar Ob.Fp. At week 26, Scl-Ab maintained MAR at similar or higher values than PTH in the face of a significantly larger Ob.Fp. These parameters were combined to form a stereological index of individual Ob vigor (Ob.S*MAR/Ob.N) that was significantly increased by Scl-Ab relative to PTH at both timepoints. Together, these data indicate that early in the course of treatment, Ob.N/Ob.S on a formative site is not affected by PTH or Scl-Ab, but Scl-Ab has a greater effect on the individual activity of the Ob. With chronic treatment, bone formation is maintained by Scl-Ab with lower Ob.N/Ob.S by maintaining increased Ob activity or vigor. Gene expression data from laser capture microdissectionenriched samples of Ob isolated from Scl-Ab-treated rat vertebrae supports an increase in Ob vigor, as reflected in significant increases in Ob functional genes as early as 6 h [2] .
The last cell of the Ob lineage subjected to quantification was the L.Ce that showed significant reduction in density and increased footprint at week 26 with Scl-Ab. This reduction may reflect an integration of changes in Ob.N/Ob.S that would have affected a large percentage of the bone surface across the treatment period. In contrast, the early decrease in L.Ce.Fp with Scl-Ab may have reflected L.Ce contraction in response to the dramatic increase in Ob.S. The 3 mg/kg Scl-Ab-treated groups displayed several of the changes observed at 50 mg/kg but more modest in effect in one or both genders. These included early transient increases in bone formation markers that were associated with increased BFR/BS, resulting in increases in bone mass primarily in trabecular bone. Quantitative changes in the Ob subpopulations at week 26 included reduction in PTb.Op, Ma.Op, Ma.St.Ce, and PTb.Op/BS as well as increased L.Ce.Fp. Notably, the significant increase in L.Ce.Fp at 3 mg/kg occurred in the absence of detectable increases in Ob.Fp. Effects on Ob.N/Ob.S and footprint at this dose may have been subtle and below the sensitivity of the methods employed but may have been reflected in changes in L.Ce.Fp that would integrate changes in Ob.N/Ob.S over the timecourse. As discussed previously, it is possible that other mechanisms may be involved that affected L.Ce.N in response to Scl-Ab, such as apoptosis. Further studies would be required to investigate the mechanism of increased L.Ce.Fp.
There were changes in Ob subpopulations related to aging that were noteworthy. Ob.N/Ob.S displayed time-dependent increases, with reciprocal decreases in Ob.Fp, and increases in progenitor populations. These data suggest that with aging, Ob lose activity or vigor and require a higher density with smaller footprint to maintain MAR; this is reflected in a reduction in the vigor index Ob.S*MAR/Ob.N and results in a greater number of progenitors required to service formative sites. In contrast, L.Ce.N and L.Ce.Fp were maintained with age, suggesting that aging results in a decrease in Ob lifespan to maintain cell density on quiescent surfaces.
Neither Scl-Ab nor PTH increased longitudinal bone growth rate in these growing rats after 4 or 26 weeks, although PTH resulted in increased femur length in both sexes. These increases are consistent with previous reports of approximately 5% increases in femur length after long-term PTH treatment in similarly aged rats [23] , an effect that has been associated with increased growth plate length [35] . Although genetic ablation of sclerostin has been associated with increased stature in patients with sclerosteosis [36] , only a minor increase in femur length was reported in female, but not male, SOST-KO mice [37] .
The present study employed robust stereological methods which, to date, have not been used to investigate quantitative changes in cell number in bone. These sensitive methods revealed that Scl-Ab can effect increases in cancellous bone mass with the same or fewer numbers of Ob by increasing Ob.Fp and increasing Ob activity or vigor compared with PTH. This reduction in density of Ob on the formative site was associated with a coordinated reduction in osteoprogenitors that was more pronounced than the effects with PTH. These time-dependent reductions in subpopulations of the Ob lineage may be integral to the greater attenuation or self-regulation of bone formation observed at the vertebra with Scl-Ab. PTH required more Ob at the formative site with correlative increased numbers of progenitors compared with Scl-Ab, indicating potentially greater stimulus for progenitor pool proliferation or differentiation.
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